Last reviewed · How we verify

NCT05571462: MAP-ABI

Mobility and Activity Patterns in Hospitalised Severe Brain Injury

Status unknown Last updated 13 March 2024
What this trial tests

trial testing Activity monitor group in Brain Injuries in 100 participants. Status unknown.

Timeline
3 November 2022
Primary endpoint
30 April 2024
30 April 2024

Quick facts

Lead sponsorChristian Riberholt
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date3 November 2022
Primary completion30 April 2024
Estimated completion30 April 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Christian Riberholt

Who can join

18 and older, any sex, with Brain Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational study is to quantify physical activity patterns in patients with severe acquired brain injury admitted for in-hospital rehabilitation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Mapping physical activity patterns in hospitalised patients with moderate to severe acquired brain injury - MAP-ABI: Protocol for an observational study
    Wagner V, Gravesen P, Ghaziani E, Olsen MH, et al · · 2023
  2. Mapping physical activity patterns in hospitalised patients with moderate to severe acquired brain injury - MAP-ABI: Protocol for an observational study.
    Wagner V, Gravesen P, Ghaziani E, Olsen MH, et al · · 2023 · PMID 38034693 · DOI 10.1016/j.heliyon.2023.e21927

Verify or expand the search:

Other recruiting trials for Brain Injuries

Currently open trials in the same condition.

Other Christian Riberholt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05571462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing